These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1943 related articles for article (PubMed ID: 23707371)

  • 1. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
    Sangro B; Carpanese L; Cianni R; Golfieri R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Van Buskirk M; Bilbao JI; Ettorre GM; Salvatori R; Giampalma E; Geatti O; Wilhelm K; Hoffmann RT; Izzo F; Iñarrairaegui M; Maini CL; Urigo C; Cappelli A; Vit A; Ahmadzadehfar H; Jakobs TF; Lastoria S;
    Hepatology; 2011 Sep; 54(3):868-78. PubMed ID: 21618574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
    Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
    Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
    Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
    Trials; 2012 Aug; 13():144. PubMed ID: 22913492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
    Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.
    Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH
    J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma.
    Iñarrairaegui M; Pardo F; Bilbao JI; Rotellar F; Benito A; D'Avola D; Herrero JI; Rodriguez M; Martí P; Zozaya G; Dominguez I; Quiroga J; Sangro B
    Eur J Surg Oncol; 2012 Jul; 38(7):594-601. PubMed ID: 22440743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
    Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
    Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.
    Kooby DA; Egnatashvili V; Srinivasan S; Chamsuddin A; Delman KA; Kauh J; Staley CA; Kim HS
    J Vasc Interv Radiol; 2010 Feb; 21(2):224-30. PubMed ID: 20022765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness.
    Xing M; Kokabi N; Camacho JC; Kooby DA; El-Rayes BF; Kim HS
    J Comp Eff Res; 2013 Jul; 2(4):435-44. PubMed ID: 24236684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.
    Hilgard P; Hamami M; Fouly AE; Scherag A; Müller S; Ertle J; Heusner T; Cicinnati VR; Paul A; Bockisch A; Gerken G; Antoch G
    Hepatology; 2010 Nov; 52(5):1741-9. PubMed ID: 21038413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.
    Kwok PC; Leung KC; Cheung MT; Lam TW; Szeto LT; Chou SQ; Chia NH; Tong CM; Yuen PK; Cheung CH; Law CK
    J Gastroenterol Hepatol; 2014 Nov; 29(11):1897-904. PubMed ID: 24734957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.
    Iñarrairaegui M; Thurston KG; Bilbao JI; D'Avola D; Rodriguez M; Arbizu J; Martinez-Cuesta A; Sangro B
    J Vasc Interv Radiol; 2010 Aug; 21(8):1205-12. PubMed ID: 20598574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
    Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
    Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
    Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
    J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma.
    Lance C; McLennan G; Obuchowski N; Cheah G; Levitin A; Sands M; Spain J; Srinivas S; Shrikanthan S; Aucejo FN; Kim R; Menon KV
    J Vasc Interv Radiol; 2011 Dec; 22(12):1697-705. PubMed ID: 21983055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.
    Sukato DC; Tohme S; Chalhoub D; Han K; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    J Vasc Interv Radiol; 2015 Jun; 26(6):816-24.e1. PubMed ID: 25824315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma.
    D'Avola D; Lñarrairaegui M; Bilbao JI; Martinez-Cuesta A; Alegre F; Herrero JI; Quiroga J; Prieto J; Sangro B
    Hepatogastroenterology; 2009; 56(96):1683-8. PubMed ID: 20214218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 98.